Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease (2020)
Attributed to:
CHARACTERISING KYNURENINE 3-MONOOXYGENASE (KMO) AS A THERAPEUTIC TARGET FOR HUNTINGTON'S DISEASE
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2020.08.06.20169524
Publication URI: http://dx.doi.org/10.1101/2020.08.06.20169524
Type: Preprint